This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Poor Study Results Sink Corcept

Shares of Corcept Therapeutics (CORT - Get Report) plummeted Friday after the company said a late-stage clinical trial intended to prove the effectiveness of its treatment for psychotic major depression missed its goal.

In one of three phase III trials, the drug, Corlux, failed to improve a target number of patients' scores on a psychiatric-symptoms rating scale by 50%, the study's main target.

Shares slumped 44 cents, or 34%, to 87 cents on trading volume that was much heavier than normal.

"The study revealed no meaningful separation in response between patients receiving Corlux and patients receiving placebo," the company said in a press release. Results from a previous trial showed an unusually high patient response to a placebo, added Corcept's president and head of development Dr. Robert Roe.

At day 56 of the trial, for example, 95% of patients given the drug, and 95% of patients taking a placebo showed at least a 50% response measured by a specific type of psychiatric-rating scale.

Corcept said the results of two of the study's secondary goals were also poor. Despite the findings, Corcept will continue to enroll patients in another phase III study of the drug. Phase III is the stage of trials conducted to support Food and Drug Administration approval.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CORT $5.98 0.00%
AAPL $127.98 0.30%
FB $83.74 0.78%
GOOG $537.50 0.40%
TSLA $205.27 0.00%

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs